MDC-STG

**MDC-STG** is an investigational Medincell long-acting injectable HIV pre-exposure prophylaxis program that uses the company's BEPO bioresorbable depot technology to deliver a PrEP active ingredient over several months after a single subcutaneous injection. Publicly available company materials describe it as a feasibility-stage internal formulation program funded by the Bill & Melinda Gates Foundation and intended to create a best-in-class long-acting HIV prevention product, but they do not clearly disclose the underlying active pharmaceutical ingredient, exact molecular target, or detailed clinical mechanism. The program appears to have remained at formulation or preclinical stage in publicly accessible disclosures, with later Medincell pipeline materials treating it as confidential or no longer explicitly listing it.